Found 19 results
[ Author(Asc)] Keyword Title Type Year
Filters: First Letter Of Last Name is K  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
C. Kurzeder, L, Z., Eisenhauer, E., Vergote, I. B., du Bois, A., D, T., Y, W., JF, G., HW, H., B, R., LC, H., Bentley, J., Wagner, U., Plante, M., Kimmig, R., and Pfisterer, J., The impact of dose intensity on the efficacy of gemcitabine plus carboplatin (GC) therapy for recurrent platinum-sensitive ovarian cancer (PSOC): A retrospective analysis of AGO-OVAR 2.5. , J Clin Oncol , vol. 29, no. suppl; abstr 5088, 2011.
J. - E. Kurtz, Kaminsky, M. C., Floquet, A., Veillard, A. S., Kimmig, R., Dorum, A., Elit, L., Buck, M., Petru, E., Reed, N. Simon, Scambia, G., Varsellona, N., Brown, C., and Pujade-Lauraine, E., Ovarian cancer in elderly patients: carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in late relapse: a Gynecologic Cancer Intergroup (GCIG) CALYPSO sub-study., Ann Oncol, vol. 22, no. 11, p. 2423, 2011.
J. - E. Kurtz, Freyer, G., Joly, F., Gladieff, L., Kaminsky, M. C., Fabbro, M., Floquet, A., Hardy-Bessard, A. C., Raban, N., Ray-Coquard, I., Pujade-Lauraine, E., and France, G. I. N. E. C. O. Group, Combined oral topotecan plus carboplatin in relapsed or advanced cervical cancer: a GINECO phase I-II trial, Anticancer Res, vol. 32, pp. 1045-9, 2012.
S. Kumagai, Sugiyama, T., Shoji, T., Michimae, H., Katsumata, N., Aoki, D., Terauchi, F., Jobo, T., Ochiai, K., and Yasuda, M., Does severe anemia caused by dose-dense paclitaxel-Carboplatin combination therapy have an effect on the survival of patients with epithelial ovarian cancer? Retrospective analysis of the Japanese gynecologic oncology group 3016 trial., Int J Gynecol Cancer, vol. 21, no. 9, pp. 1585-91, 2011.
K. Kudoh, Takano, M., Kouta, H., Kikuchi, R., Kita, T., Miyamoto, M., Watanabe, A., Kato, M., Goto, T., and Kikuchi, Y., Effects of bevacizumab and pegylated liposomal doxorubicin for the patients with recurrent or refractory ovarian cancers, Gynecol Oncol, vol. 122, pp. 233-7, 2011.
G. B. Kristensen, Vergote, I. B., Stuart, G. C. E., Del Campo, J. M., Kaern, J., Lopez, A. B., Eisenhauer, E., Åvall-Lundqvist, E., Ridderheim, M., Havsteen, H., Mirza, M. R., Scheistroen, M., and Vrdoljak, E., First-line treatment of ovarian cancer FIGO stages IIb-IV with paclitaxel/epirubicin/carboplatin versus paclitaxel/carboplatin., Int J Gynecol Cancer, vol. 13 Suppl 2, pp. 172-7, 2003.
G. B. Kristensen, Perren, T. J., Qian, W., Pfisterer, J., Ledermann, J. A., Joly, F., Carey, M. S., Beale, P., Cervantes, A., and Oza, A. M., Result of interim analysis of overall survival in the phase III randomized trial of bevacizumab in women with newly diagnosed ovarian cancer. , J Clin Oncol , vol. 29, no. suppl; abstr LBA5006, 2011.
S. Kommoss, du Bois, A., Ridder, R., Trunk, M. J., Schmidt, D., Pfisterer, J., Kommoss, F., and -OVAR, A. G. O., Independent prognostic significance of cell cycle regulator proteins p16(INK4a) and pRb in advanced-stage ovarian carcinoma including optimally debulked patients: a translational research subprotocol of a randomised study of the Arbeitsgemeinschaft Gynaek, Br J Cancer, vol. 96, pp. 306-13, 2007.
H. C. Kitchener and Trimble, E. L., Endometrial cancer state of the science meeting., Int J Gynecol Cancer, vol. 19, no. 1, pp. 134-40, 2009.
H. C. Kitchener, Management of endometrial cancer., Eur J Surg Oncol, vol. 32, no. 8, pp. 838-43, 2006.
H. C. Kitchener, Hoskins, W. J., Small, W., Thomas, G. M., Trimble, E. L., and Group, C. Cancer Con, The development of priority cervical cancer trials: a Gynecologic Cancer InterGroup report, Int J Gynecol Cancer, vol. 20, pp. 1092-100, 2010.
H. C. Kitchener, Adjuvant chemotherapy improves survival after resection of stage 1 ovarian cancer., Cancer Treat Rev, vol. 31, no. 4, pp. 323-7, 2005.
H. M. Keys, Roberts, J. A., Brunetto, V. L., Zaino, R. J., Spirtos, N. M., Bloss, J. D., Pearlman, A., Maiman, M. A., Bell, J. G., and Group, G. Oncology, A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study, Gynecol Oncol, vol. 92, pp. 744-51, 2004.
S. B. Kaye, Paul, J., Cassidy, J., Lewis, C. R., Duncan, I. D., Gordon, H. K., Kitchener, H. C., Cruickshank, D. J., Atkinson, R. J., Soukop, M., Rankin, E. M., Davis, J. A., Reed, N. Simon, Crawford, S. M., MacLean, A., Parkin, D., Sarkar, T. K., Kennedy, J., Symonds, R. P., and Group, S. Gynaecolog, Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer. Scottish Gynecology Cancer Trials Group, J Clin Oncol, vol. 14, pp. 2113-9, 1996.
S. B. Kaye and Group, S. Gynaecolog, The integration of docetaxel into first-line chemotherapy for ovarian cancer, Int J Gynecol Cancer, vol. 11 Suppl 1, pp. 31-3, 2001.
N. Katsumata, Yasuda, M., Takahashi, F., Isonishi, S., Jobo, T., Aoki, D., Tsuda, H., Sugiyama, T., Kodama, S., Kimura, E., Ochiai, K., Noda, K., and Group, J. Gynecologi, Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial, Lancet, vol. 374, pp. 1331-8, 2009.
N. Katsumata, Yasuda, M., Isonishi, S., Takahashi, F., Michimae, H., Kimura, E., Aoki, D., Jobo, T., Kodama, S., Terauchi, F., Sugiyama, T., Ochiai, K., and Group, J. Gynecologi, Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial, Lancet Oncol, vol. 14, pp. 1020-6, 2013.
K. Katherine, Julia, B., Valerie, B., Oza, A. M., and Stephanie, L., Ovarian Cancer and BRCA1/2 Testing: Opportunities to improve clinical care and disease prevention , Frontiers in Oncology , vol. 6, no. 00119 , 2016.
B. K, Kaern, J., Simonsen, E., Piccart, M. J., G, H. Boes, Timmers, P., Roy, J. - A., Pecorelli, S., Stuart, G. C. E., James, K., Cassidy, J., and Kaye, S. B., Is cisplatin-taxol the standard treatment in advanced ovarian cancer., Eur.J.Can. , vol. 33, no. 8, 1997.